Treatment with compound 4c inhibited translocation of NF-κB-p65 in CML cells compared with non-treated (NT) cells; NF-B-p65 antibodies stained the nucleus more strongly in cells treated with TNFα alone. This evidence concerns the gene NFKB1 and chronic myelogenous leukemia, BCR-ABL1 positive.